medwireNews : Study findings reported in Rheumatology suggest that anti-Sjögren’s syndrome/scleroderma autoantigen 1 (SSSCA1) antibodies may warrant further investigation as a biomarker for cancer risk among patients with systemic sclerosis (SSc).

A monthly selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

How can rheumatologists respond to the challenges associated with rituximab use during the pandemic?

The current analysis included data for 553 people with at least one follow-up visit and a median time since the onset of Raynaud's phenomenon of 4 years.

3–9 November: Keep up with the latest news and interviews from the conference.

Perspective on the approval of anifrolumab and the importance of endpoints in lupus trials.

5 – 9 November: Preview the conference with session recommendations and updates on upcoming coverage.

How will the FAST trial results impact regulatory guidance & clinical practice?

Experts discuss the increasing use of telemedicine in rheumatology during the COVID-19 pandemic.

For the HAQ, the greatest differences over 7 years were observed in the domains that focused on pain and Raynaud’s syndrome.

Similarly, antibodies to the aminoacyl t-RNA synthetases (ARS) (see Table 1) identify a cohort of anti-synthetase syndrome patients where ILD is the most common and severe manifestation.

Two studies presented at EULAR 2017 have highlighted new tools that could help diagnose systemic sclerosis in the early stages, supporting the EULAR campaign: “Don’t delay, Connect Today!”